What Clinicians and Patients Need (and Want!) to Know About the Value for Money of New Health Innovations

Market access does not automatically mean patient access. In order for patients to benefit from innovative medicines and medtech solutions, also clinicians and patient advocacy groups need to understand their value and value for money.

Prof. Dr. Lieven Annemans, well known for his broad HTA expertise and excellent presentation skills, will provide his insights as to what the principles and methods of health economic evaluations and HTA mean for clinicians and patients:
 

• How to talk about value for money to clinicians and patient advocacy groups

• How to align the clinical and the health economic view 

• How to go beyond the QALY to account for what matters to patients

• How to deal with evidence gaps: the increasing role of Real World Evidence 

Register now ➤

Educational Webinar with Prof. Dr. Lieven Annemans

Register now ➤

Please note that this webinar is only open to managers working in the pharma/biotech/medtech industry.  
For your registration to be approved, please enter your COMPANY EMAIL address.

(*) if you cannot attend the webinar, please note that a recorded playback 
will be sent to all registrants after the webinar.